NO318644B1 - Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom. - Google Patents
Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom. Download PDFInfo
- Publication number
- NO318644B1 NO318644B1 NO19944752A NO944752A NO318644B1 NO 318644 B1 NO318644 B1 NO 318644B1 NO 19944752 A NO19944752 A NO 19944752A NO 944752 A NO944752 A NO 944752A NO 318644 B1 NO318644 B1 NO 318644B1
- Authority
- NO
- Norway
- Prior art keywords
- dnase
- human dnase
- isoaspartate
- deamidated
- containing human
- Prior art date
Links
- 102000016911 Deoxyribonucleases Human genes 0.000 title claims abstract description 297
- 108010053770 Deoxyribonucleases Proteins 0.000 title claims abstract description 297
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000000034 method Methods 0.000 title claims description 44
- 208000019693 Lung disease Diseases 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title claims description 11
- 239000000463 material Substances 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000009825 accumulation Methods 0.000 title claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 title description 16
- 229940009098 aspartate Drugs 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 238000000926 separation method Methods 0.000 claims abstract description 20
- 239000004033 plastic Substances 0.000 claims abstract description 17
- 229920003023 plastic Polymers 0.000 claims abstract description 17
- 239000011521 glass Substances 0.000 claims description 20
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 15
- 229920005989 resin Polymers 0.000 claims description 15
- 239000003729 cation exchange resin Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 239000003708 ampul Substances 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 201000008827 tuberculosis Diseases 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 102000003839 Human Proteins Human genes 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 241000894007 species Species 0.000 abstract description 9
- 238000012512 characterization method Methods 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 36
- 108090000765 processed proteins & peptides Proteins 0.000 description 34
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 230000006240 deamidation Effects 0.000 description 22
- 125000003275 alpha amino acid group Chemical group 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 238000004587 chromatography analysis Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 238000012856 packing Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 230000002255 enzymatic effect Effects 0.000 description 12
- 238000003860 storage Methods 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 10
- 108090000631 Trypsin Proteins 0.000 description 10
- 239000012588 trypsin Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 8
- 101000863721 Homo sapiens Deoxyribonuclease-1 Proteins 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000001110 calcium chloride Substances 0.000 description 8
- 229910001628 calcium chloride Inorganic materials 0.000 description 8
- 235000011148 calcium chloride Nutrition 0.000 description 8
- 230000029087 digestion Effects 0.000 description 7
- 238000013507 mapping Methods 0.000 description 7
- 241000699802 Cricetulus griseus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 6
- 108010067396 dornase alfa Proteins 0.000 description 6
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 229940023913 cation exchange resins Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 239000006167 equilibration buffer Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 3
- NRGZTHQFAQCJCQ-UHFFFAOYSA-N 4-nitrophenyl hydrogen phenylphosphonate Chemical compound C=1C=CC=CC=1P(=O)(O)OC1=CC=C([N+]([O-])=O)C=C1 NRGZTHQFAQCJCQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000276498 Pollachius virens Species 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- -1 sulfopropyl groups Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 108010072106 tumstatin (74-98) Proteins 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 229920006317 cationic polymer Polymers 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000088 plastic resin Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 101001006892 Homo sapiens Krueppel-like factor 10 Proteins 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 102100027798 Krueppel-like factor 10 Human genes 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010044314 Tracheobronchitis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000012561 harvest cell culture fluid Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000000409 histolytic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/815—Enzyme separation or purification by sorption
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/895,300 US5279823A (en) | 1992-06-08 | 1992-06-08 | Purified forms of DNASE |
| PCT/US1993/005136 WO1993025670A1 (en) | 1992-06-08 | 1993-05-28 | Purified forms of dnase |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO944752D0 NO944752D0 (no) | 1994-12-08 |
| NO944752L NO944752L (no) | 1994-12-08 |
| NO318644B1 true NO318644B1 (no) | 2005-04-25 |
Family
ID=25404292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19944752A NO318644B1 (no) | 1992-06-08 | 1994-12-08 | Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom. |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US5279823A (ro) |
| EP (2) | EP1013284B1 (ro) |
| JP (1) | JP3383307B2 (ro) |
| KR (2) | KR100302092B1 (ro) |
| AT (2) | ATE195340T1 (ro) |
| AU (1) | AU682822B2 (ro) |
| BG (1) | BG62335B1 (ro) |
| BR (1) | BR9306670A (ro) |
| CA (1) | CA2137237C (ro) |
| CZ (1) | CZ293105B6 (ro) |
| DE (3) | DE4392749T1 (ro) |
| DK (1) | DK0644932T3 (ro) |
| ES (1) | ES2150447T3 (ro) |
| FI (1) | FI945549A (ro) |
| GB (1) | GB2282140B (ro) |
| GE (1) | GEP20002300B (ro) |
| GR (1) | GR3034718T3 (ro) |
| HU (1) | HU219549B (ro) |
| IL (1) | IL105724A (ro) |
| MD (1) | MD960288A (ro) |
| NO (1) | NO318644B1 (ro) |
| NZ (1) | NZ253559A (ro) |
| PL (1) | PL175873B1 (ro) |
| PT (1) | PT644932E (ro) |
| RO (1) | RO117188B1 (ro) |
| RU (1) | RU2238320C2 (ro) |
| SK (1) | SK282957B6 (ro) |
| TJ (1) | TJ396B (ro) |
| UA (1) | UA46693C2 (ro) |
| WO (1) | WO1993025670A1 (ro) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE176924T1 (de) * | 1988-12-23 | 1999-03-15 | Genentech Inc | Verfahren zur herstellung von menschlicher dnase |
| US5279823A (en) | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| JP2986215B2 (ja) * | 1994-03-04 | 1999-12-06 | ジェネンテック インコーポレイテッド | Ｄｎアーゼ含有医薬製剤 |
| US6383788B1 (en) * | 1994-03-04 | 2002-05-07 | Genentech, Inc. | Minimizing thermally induced aggregation of DNase in solution with calcium |
| WO1995030428A1 (en) * | 1994-05-05 | 1995-11-16 | Human Genome Sciences, Inc. | Human dnase |
| US6251648B1 (en) | 1998-04-03 | 2001-06-26 | Human Genome Sciences, Inc. | Gene encoding human Dnase |
| US5830744A (en) * | 1995-06-06 | 1998-11-03 | Human Genome Sciences, Inc. | Gene encoding human Dnase |
| US5602110A (en) * | 1994-08-31 | 1997-02-11 | Case Western Reserve University | Method and composition for treating cystic fibrosis |
| EP0754751B1 (en) * | 1994-09-06 | 2001-09-19 | Seiichi Tanuma | Novel deoxyribonuclease |
| US5863563A (en) * | 1994-10-20 | 1999-01-26 | Alphagene Inc. | Treatment of pulmonary conditions associated with insufficient secretion of surfactant |
| US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
| SK284191B6 (sk) | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
| US6482626B2 (en) * | 1996-02-05 | 2002-11-19 | Genentech, Inc. | Human DNase |
| EP0879289B1 (en) * | 1996-02-05 | 2006-07-05 | Genentech, Inc. | Human dnase resistant to actin inhibition |
| US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| CA2399464C (en) * | 2000-02-11 | 2008-10-07 | Medic-Aid Limited | Drug delivery apparatus |
| US8820316B2 (en) * | 2000-02-11 | 2014-09-02 | Respironics Respiratory Drug Delivery (Uk) Ltd | Drug delivery apparatus |
| DK1285080T3 (da) | 2000-05-31 | 2008-12-01 | Novartis Vaccines & Diagnostic | Fremgangsmåde til oprensning af alphavirusreplikonpartikler |
| MD20010375A (ro) * | 2001-11-19 | 2003-06-30 | АНДРИЕВСКИ Сергей | Malaxor |
| MD2260C2 (ro) * | 2001-11-22 | 2004-03-31 | АНДРИЕВСКИ Сергей | Malaxor |
| CA2496060C (en) | 2002-09-11 | 2015-08-04 | Genentech, Inc. | Protein purification by ion exchange chromatography |
| US7067298B2 (en) | 2003-03-31 | 2006-06-27 | Ambion, Inc. | Compositions and methods of using a synthetic Dnase I |
| US7595179B2 (en) | 2004-04-19 | 2009-09-29 | Applied Biosystems, Llc | Recombinant reverse transcriptases |
| JP2008529495A (ja) * | 2005-02-04 | 2008-08-07 | グラクソ グループ リミテッド | 異種ポリペプチド発現の最適化 |
| KR100655438B1 (ko) * | 2005-08-25 | 2006-12-08 | 삼성전자주식회사 | 자기 기억 소자 및 그 형성 방법 |
| WO2007143206A2 (en) * | 2006-06-02 | 2007-12-13 | Epicentre Technologies | Compositions and methods for removal of dna from a sample |
| WO2008047364A2 (en) * | 2006-10-18 | 2008-04-24 | Periness Ltd. | Method and pharmacological composition for the diagnosis and treatment of male sub-fertility |
| EP2840090B1 (en) | 2007-10-30 | 2018-02-21 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
| WO2009123950A2 (en) * | 2008-03-31 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Chimera comprising bacterial cytotoxin and methods of using the same |
| GB2474225A (en) * | 2009-07-21 | 2011-04-13 | Biotec Pharmacon Asa | DNase for decontamination of reverse transcription and amplification reactions |
| EP3318635A1 (en) | 2011-04-21 | 2018-05-09 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US9603906B2 (en) | 2012-02-01 | 2017-03-28 | Protalix Ltd. | Inhalable liquid formulations of DNase I |
| CN103920144B (zh) * | 2013-01-15 | 2016-09-14 | 吴庄民 | 重组人的脱氧核糖核酸酶i的新应用 |
| KR20170026521A (ko) * | 2014-06-25 | 2017-03-08 | 제이에이치엘 바이오테크 인코포레이티드 | 단백질의 정제를 위한 방법 및 시약 |
| EP3214172B1 (en) | 2014-10-31 | 2019-02-13 | JCR Pharmaceuticals CO., LTD. | Method for producing remcombinant human dnasei |
| WO2017019876A1 (en) * | 2015-07-28 | 2017-02-02 | University Of Massachusetts | Transgenic expression of dnase i in vivo delivered by an adeno-associated virus vector |
| US11060088B2 (en) | 2016-02-12 | 2021-07-13 | University Of Massachusetts | Anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| CN110199016B (zh) | 2016-11-17 | 2024-08-16 | 艾欧凡斯生物治疗公司 | 残余肿瘤浸润淋巴细胞及其制备和使用方法 |
| EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
| US20230226138A1 (en) | 2020-06-01 | 2023-07-20 | Black Cat Bio Limited | Compositions and methods for treating infections and netopathy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2801956A (en) * | 1954-08-24 | 1957-08-06 | Merck & Co Inc | Process for preparing pancreatic desoxyribonuclease |
| US2834710A (en) * | 1955-06-29 | 1958-05-13 | Merck & Co Inc | Pancreatic desoxyribonuclease penicillin composition and process of preparation |
| US3208908A (en) * | 1961-11-16 | 1965-09-28 | Parke Davis & Co | Fibrinolysin-desoxyribonuclease for enzymatic debridement |
| US3663690A (en) * | 1969-08-12 | 1972-05-16 | Hoechst Co American | Mucolytic composition and method of treatment of broncho-pulmonary disorders therewith |
| CA1059937A (en) * | 1975-03-25 | 1979-08-07 | Boen T. Khouw | Isolation and purification of deoxyribonuclease |
| US5077211A (en) * | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| ATE176924T1 (de) * | 1988-12-23 | 1999-03-15 | Genentech Inc | Verfahren zur herstellung von menschlicher dnase |
| US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
-
1992
- 1992-06-08 US US07/895,300 patent/US5279823A/en not_active Expired - Lifetime
-
1993
- 1993-05-18 IL IL105724A patent/IL105724A/xx not_active IP Right Cessation
- 1993-05-28 UA UA95018026A patent/UA46693C2/uk unknown
- 1993-05-28 GE GEAP19932382A patent/GEP20002300B/en unknown
- 1993-05-28 CZ CZ19943032A patent/CZ293105B6/cs not_active IP Right Cessation
- 1993-05-28 EP EP00101817A patent/EP1013284B1/en not_active Expired - Lifetime
- 1993-05-28 RO RO94-01956A patent/RO117188B1/ro unknown
- 1993-05-28 HU HU9403512A patent/HU219549B/hu unknown
- 1993-05-28 MD MD96-0288A patent/MD960288A/ro unknown
- 1993-05-28 EP EP93914258A patent/EP0644932B1/en not_active Expired - Lifetime
- 1993-05-28 KR KR1019940704462A patent/KR100302092B1/ko not_active IP Right Cessation
- 1993-05-28 ES ES93914258T patent/ES2150447T3/es not_active Expired - Lifetime
- 1993-05-28 PT PT93914258T patent/PT644932E/pt unknown
- 1993-05-28 RU RU94046424A patent/RU2238320C2/ru active
- 1993-05-28 TJ TJ96000330A patent/TJ396B/xx unknown
- 1993-05-28 PL PL93306723A patent/PL175873B1/pl unknown
- 1993-05-28 DE DE4392749T patent/DE4392749T1/de not_active Ceased
- 1993-05-28 BR BR9306670A patent/BR9306670A/pt not_active Application Discontinuation
- 1993-05-28 AT AT93914258T patent/ATE195340T1/de active
- 1993-05-28 AT AT00101817T patent/ATE455557T1/de active
- 1993-05-28 DE DE69334317T patent/DE69334317D1/de not_active Expired - Lifetime
- 1993-05-28 SK SK1495-94A patent/SK282957B6/sk not_active IP Right Cessation
- 1993-05-28 WO PCT/US1993/005136 patent/WO1993025670A1/en active IP Right Grant
- 1993-05-28 DK DK93914258T patent/DK0644932T3/da active
- 1993-05-28 CA CA002137237A patent/CA2137237C/en not_active Expired - Lifetime
- 1993-05-28 NZ NZ253559A patent/NZ253559A/en not_active IP Right Cessation
- 1993-05-28 JP JP50152894A patent/JP3383307B2/ja not_active Expired - Lifetime
- 1993-05-28 KR KR1020017003922A patent/KR100323357B1/ko not_active IP Right Cessation
- 1993-05-28 GB GB9423695A patent/GB2282140B/en not_active Expired - Lifetime
- 1993-05-28 DE DE69329200T patent/DE69329200T2/de not_active Expired - Lifetime
- 1993-05-28 AU AU43981/93A patent/AU682822B2/en not_active Expired
-
1994
- 1994-11-25 FI FI945549A patent/FI945549A/fi not_active IP Right Cessation
- 1994-12-02 BG BG99234A patent/BG62335B1/bg unknown
- 1994-12-08 NO NO19944752A patent/NO318644B1/no not_active IP Right Cessation
-
1995
- 1995-06-02 US US08/458,367 patent/US5783433A/en not_active Expired - Lifetime
-
2000
- 2000-08-11 US US09/638,112 patent/US6440412B1/en not_active Expired - Fee Related
- 2000-10-30 GR GR20000402407T patent/GR3034718T3/el unknown
-
2002
- 2002-05-22 US US10/155,407 patent/US6932965B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO318644B1 (no) | Fremgangsmate omfattende separering av isoaspartatholdig og ikke-isoaspartatholdig human-DNase fra en blanding derav, renset isoaspartatholdig human-DNase og ikke-aspartatholdig human-DNase, farmasoytisk preparat samt anvendelse av preparatet ved fremstilling av et medikament for behandling av en pasient som har en akkumulering av purulent materiale eller pulmonar sykdom. | |
| Gamm et al. | The type II isoform of cGMP-dependent protein kinase is dimeric and possesses regulatory and catalytic properties distinct from the type I isoforms | |
| Shapiro et al. | Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis | |
| US7063971B2 (en) | Phosphodiesterase enzymes | |
| US6325989B1 (en) | Form of dipeptidylpeptidase IV (CD26) found in human serum | |
| EP0756636A1 (en) | Chondroitinases i and ii, methods of preparation, and use thereof | |
| Vischer et al. | Hexokinase isoenzymes of RIN-m5F insulinoma cells. Expression of glucokinase gene in insulin-producing cells | |
| Wang et al. | Glycogen and related polysaccharides inhibit the laforin dual-specificity protein phosphatase | |
| Watanabe et al. | Activation of calcineurin A subunit phosphatase activity by its calcium-binding B subunit | |
| Miller et al. | Human mast cell proteases and mast cell heterogeneity | |
| Epple et al. | Both lysine-clusters of the NH2-terminal prion-protein fragment PrP23-110 are essential for t-PA mediated plasminogen activation | |
| Daniele et al. | Hunter syndrome: presence of material cross-reacting with antibodies against iduronate sulfatase | |
| US7052895B2 (en) | Phosphodiesterase enzymes | |
| Sada et al. | Activation of p72syk by thrombin in a cell-free system | |
| KR20010085287A (ko) | 단백질 타이로신 포스파타아제의 세포내 도메인에 대한 항체 | |
| Wille et al. | Biophysical investigation of human heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A: a mutual effect of enzyme oligomerisation and glycosaminoglycan ligand binding | |
| Sugahara et al. | Regulation of serum glycosaminoglycan sulfotransferase activities: inhibition by sulfated glycosaminoglycans and activation by polyamines and basic peptides including a polylysine-containing segment of the c-Ki-ras 2 protein | |
| Marie et al. | Adenylosuccinate lyase deficiency: from the clinics to molecular biology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |